Publications by authors named "M K Wooddell"
Article Synopsis
- Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
- It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
- Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
Hepatic safety data assessment from the TURALIO (pexidartinib) Risk Evaluation and Mitigation Strategy (tREMS) Program. Retrospective 3-year assessment (August 2019 to June 2022) of hepatic events from the TURALIO® (pexidartinib) Risk Evaluation and Mitigation Strategy Program. A total of 451 patients, 369 prescribers, 2 wholesalers/distributors and 2 pharmacies were enrolled and certified.
View Article and Find Full Text PDFReal-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. To characterize drug utilization and treatment patterns in TGCT patients.
View Article and Find Full Text PDFTo evaluate treatment patterns, healthcare resource utilization (HRU) and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. A retrospective cohort study, using the IQVIA PharMetrics Plus claims database from 1 April 2011 to 30 November 2021, identified PTCL patients receiving systemic treatments. Three mutually exclusive subcohorts were created based on line of therapy (LOT): 1LOT, 2LOT and ≥3LOT.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated cardiac events in patients with acute myeloid leukemia (AML), revealing that 4.6% of newly diagnosed and 3.6% of treated patients experienced fatal cardiac events over time.
- Risk factors for these events included prior heart disease, older age (≥ 65), previous cardiac issues, and receiving non-intensive chemotherapy.
- Additionally, the research found a high overall incidence of non-fatal cardiac events and significant impacts on survival for those who suffered severe cardiac complications during treatment.